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ABSTRACT 
 
Aim: This research was aimed to assess the potential for inhibition of protein binding of phenytoin 
by tizoxanide in human plasma. Phenytoin was used because studies have proven to be a highly 
plasma protein-bound drug with a narrow therapeutic index and non-linear pharmacokinetics. 
Tizoxanide is another highly protein-bound active metabolite of an anti-infective prodrug 
nitazoxanide. Both drugs are expected to be administered together due to their therapeutic 
indications.  
Study Design: The study was divided into two phases. Phase 1 produced a reference line of 
phenytoin protein binding values. Phase 2 was conducted to reveal the effect of the interactant 
tizoxanide on the protein binding of phenytoin. The results obtained from phase 1 were compared 
with those of phase 2.  
Methodology: Protein binding of phenytoin was studied using a centrifugal ultrafiltration method. 
Protein binding of three phenytoin concentrations was studied: 25, 50, and 100 µg/mL. The 
concentrations of phenytoin were analyzed by validated HPLC method. Each experiment was 
performed in triplicate. 
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Results: Co-administration of tizoxanide significantly inhibited protein binding of phenytoin for all 
concentrations tested. Tizoxanide increased unbound fraction (fu) of phenytoin by 4.4, 3.7, and 2.8-
fold for concentration of 25, 50, and 100 µg/ml, respectively. Phenytoin was displaced from protein 
binding sites what resulted in amplified unbound plasma levels of the antiepileptic drug.  
Conclusion: Tizoxanide significantly inhibited protein binding of phenytoin in human plasma. The 
interaction could potentially result in altered elimination and increased toxicity of phenytoin leading 
to neuronal side effects and hypersensitivity reactions. Caution also should be taken when 
administering nitazoxanide concurrently with other highly plasma protein-bound drugs, especially 
drugs with narrow therapeutic indices, as competition for binding sites may occur. 
 
 
Keywords: Protein binding; drug-drug interaction; phenytoin; tizoxanide. 
 
1. INTRODUCTION  
 
Patients treated with antiepileptic drugs 
experience variability in therapeutic outcomes 
including adverse effects. This is due to genetic 
polymorphisms affecting metabolizing enzymes 
and drug transporters, plasma/tissue protein 
binding, and drug-drug interactions [1]. In 
reference to genetic polymorphisms, ultra-rapid, 
intermediate, and poor metabolizers demonstrate 
differences in the CYP450 enzymatic process 
and therefore, show variabilities in therapeutic 
response and drug toxicity
1
. Plasma protein 
binding, another determinant of a drug’s 
therapeutic effect, can affect pharmacokinetics 
(PK) and pharmacodynamics (PD) of drugs
 
[2]. 
Drugs in the body exist in two forms bound and 
unbound (free). Bound drugs do not elicit a 
therapeutic response because bound drugs are 
not dynamically distributed to target organs and 
don’t have affinity to target receptors. However, 
free drugs reach their active sites, interact with 
receptors and produce therapeutic effect. 
Therefore, only unbound drugs are predictors of 
a clinical efficacy or toxicity.  
 
Plasma proteins include albumins, ɑ, β, and ɣ 
globulins, lipoproteins, and glycoproteins [3]. The 
concentration of albumins is much greater than 
concentrations of other proteins in human 
plasma. Binding to blood proteins depends on 
the physicochemical properties of drugs. Acidic 
compounds are typically bound to albumins, 
while basic medications connect to globulins.   
 
Plasma protein binding interactions are 
categorized as displacement reactions. 
Displacement interactions can be specific or non-
specific, competitive or non-competitive. 
Competitive displacements are leading drug-drug 
reactions among all protein binding interactions. 
The consequence of the drug-drug reaction is 
increased free plasma concentrations of the 
displaced medication. In turn, this impacts drug’s 
pharmacokinetics parameters: volume of 
distribution and clearance
 
[3]. Outcome of the 
protein binding interaction can be dangerous if 
the displaced medication is highly bound to blood 
proteins. Additional clinical risks include non-
linear pharmacokinetics and/or narrow 
therapeutic window of the affected drug. Such 
drug-drug interaction may lead to exaggerated 
therapeutic response as well as to acute and 
chronic toxicity. For this reason, each drug 
interaction is unique and should be analyzed on 
a case-by-case basis. The simplified approach to 
protein binding interactions is not ideal as each 
active pharmaceutical ingredient possess 
pharmacologically independent characteristics. 
Measurement rather than estimation of free drug 
levels should be used to achieve safety and 
efficacy of highly protein bound medications.  
 
Phenytoin (PHT), 5,5-diphenylimidazolidine-2,4-
dione (Dilantin™) is an anticonvulsant 
medication indicated for the management of 
generalized tonic clonic seizures, complex partial 
seizures, and for the prevention of seizures after 
head trauma and neurosurgery [4]. Multiple 
unlabeled indications of phenytoin include the 
management of trigeminal neuralgia, syndrome 
of inappropriate antidiuretic hormone (SIADH), 
torsade de pointes, and arrhythmias [4]. The 
drug is rapidly distributed to the brain where an 
equilibrium in plasma and brain concentrations is 
achieved. Phenytoin is metabolized by CYP2C9 
and CYP2 C19 enzymes and is a broad-based 
inducer of cytochrome P450 system. Phenytoin 
is susceptible to metabolic drug interactions. 
Cimetidine, valproic acid, amiodarone, 
chloramphenicol, isoniazid, disulfiram, 
and omeprazole inhibit phenytoin metabolism 
and increase phenytoin blood concentrations [5]. 
As inducer PHT increases metabolism of some 
narrow therapeutic ranges drugs such as 
phenobarbital, cyclosporine, carbamazepine, 
tacrolimus, and warfarin [5]. Moreover, phenytoin 
is narrow therapeutic range drug with nonlinear, 
Michaelis-Menten kinetics [4,6,7]. The clearance 
and half-life of phenytoin are not constant and 
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depend on phenytoin plasma levels. Studies 
discovered that phenytoin is approximately 90% 
bound to plasma albumins while the unbound 
form is responsible for pharmacologic activity 
[7,8,9,10]. Since phenytoin is highly bound to 
albumins, conditions that affect albumin levels 
can also affect the unbound phenytoin 
concentrations. Disease-causing 
hypoalbuminemia such as end-stage renal 
disease (ESRD), burns, hepatic cirrhosis, 
nephrotic syndrome, pregnancy, and cystic 
fibrosis increase the fraction of unbound 
phenytoin [6,11]. High free levels of PHT can 
lead to exaggerated pharmacologic response 
and toxicity. Endogenous (bilirubin) and/or 
exogenous compounds might alter protein 
binding of phenytoin as well. Drugs that are 
highly bound to albumins and cause inhibition of 
protein binding of PHT include warfarin, valproic 
acid, and some highly bound nonsteroidal anti-
inflammatory medications [12,13,14]. 
Unbound phenytoin plasma concentrations 
should be measured in patients with altered 
phenytoin plasma protein binding [15]. When 
unbound phenytoin concentrations are 
unavailable, corrected phenytoin levels typically 
are calculated.  
 
Nitazoxanide, also known by the brand 
names Alinia® and Annita®, is a synthetic 
nitrothiazolyl-salicylamide derivative belonging to 
a class of thiazolides [16,17]. Nitazoxanide is 
a broad-spectrum antiparasitic and antiviral drug 
that is used for the treatment of 
various helminthic, protozoal, and viral infections 
[16,18,19,20,21]. Recently nitazoxanide was 
purposed for the treatment of influenza [20,22] 
and also was investigated as a potential therapy 
for chronic hepatitis B and C, rotavirus 
and norovirus gastroenteritis [20,23,24,25,26].  
 
Nitazoxanide is a prodrug that rapidly hydrolyzed 
to an active metabolite tizoxanide (TZX) [17,27]. 
The half-life of nitazoxanide in the plasma is very 
short, approximately 6 minutes [28]. Tizoxanide 
is highly bound to plasma proteins (>99%), 
mostly to plasma albumin, as result of its acidic 
property [29,30]. The half-life of TZX in plasma is 
approximately 1.5 h [31,32]. 
 
Nitazoxanide is a compound that is expected to 
be co-administered with phenytoin clinically and 
its active metabolite has the potential to alter 
phenytoin protein binding. No drug-drug protein 
binding interaction studies have been reported 
for phenytoin and nitazoxanide and/or tizoxanide 
 
The aim of this research was to identify the 
possibility of displacement interaction between 
phenytoin and tizoxanide. 
 
2. MATERIALS AND METHODS 
 
2.1 Materials  
 
Phenytoin, DMSO, methanol, HPLC water, 
potassium dihydrogen phosphate, and other 
chemicals were obtained from Sigma-Aldrich (St 
Louis, MO). Tizoxanide was purchased from 
Cayman chemicals (Tallinn, Estonia). Human 
plasma was obtained from Valley Biochemical, 
Winchester, MA. HPLC filters (0.45 um, 47 mm) 
were purchased from Pall Life Science (Port 
Washington, NY). Amicon Centrifree YM-30 
centrifugal filter units were obtained from 
Millipore (Billerica, MA) 
 
2.2 Study Groups  
 
The study was divided into phases 1 and 2. 
Phase 1 produced a reference line of phenytoin 
protein binding values. Phase 2 was conducted 
to reveal the effect of the interactant tizoxanide 
on the protein binding of phenytoin. The 
interactant was chosen based on the possibility 
of a co-administration with phenytoin in clinical 
practice and its protein binding characteristics. 
The results obtained from phase 1 were 
compared with those of phase 2. Each 
experiment was performed in triplicate.  
 
Analysis of variance (ANOVA) was applied to 
assess differences in mean values of phenytoin 
binding. This statistical method determined the 
significant differences in protein binding between 
the two study groups. Statistical significance was 
detected at a p-value<0.05. 
 
2.3 HPLC Method for Phenytoin 
 
The concentrations of phenytoin were analyzed 
using validated High Liquid Performance 
Chromatography (HPLC) technique. Peak 
separation was achieved by C18 column (250 x 
4.6 mm, 5 µm, 100 Å) through isocratic elution. 
The stationary phase was temperature controlled 
at 25°C. An ultraviolet detection wavelength of 
250 nm was used to measure phenytoin peaks. 
Mobile phase was prepared from 40% phosphate 
buffer (pH 2.8) and 60% methanol. Other HPLC 
variables include a constant flow rate of 0.7 
mL/min, a run time of 10 minutes, and an 
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injection volume of 20 µL. Phenytoin retention 
time was 7.9 minutes  
 
2.4 Protein Binding Determination  
 
A preliminary work was completed to assess 
nonspecific binding of phenytoin to the 
micropartition system (Amicon Centrifree YM-30 
System). Three concentrations of phenytoin were 
studied (25, 50 and 100 µg/mL). Ultrafiltration 
units with aqueous solutions of phenytoin were 
centrifuged at a relative force of 2000 g for 20 
minutes. The ultrafiltrates were used to evaluate 
nonspecific binding of the drug to the 
micropartition devices. The concentrations of 
phenytoin in filtrates were measured by HPLC. 
Each experiment was done in triplicate. 
 
Following the assessment of nonspecific binding 
was an analysis of phenytoin binding to plasma 
proteins. The investigation was performed at 
physiologic temperature (37°C) and pH. Human 
plasma was spiked with stock solution of 
phenytoin to produce samples of the following 
concentrations: 25 µg/mL, 50 µg/mL, and 100 
µg/mL. Tizoxanide was used only for phase 2 
trials. Concentration of TZX was 500 µg/mL in 
each sample. The resulting solutions were 
incubated at 37°C for 30 minutes. One mL of 
each sample was added to Amicon Centrifree 
devices and centrifuged for 20 minutes at 2000 
g. The ultrafiltrated samples were analyzed for 
measuring free phenytoin concentrations by 
previously mentioned HPLC method. All tests 
were performed in triplicate. 
 
2.5 Data Analysis 
 
The fraction unbound (fu) of phenytoin was 
calculated as a ratio of unbound (free) 
concentration to total phenytoin concentration in 
both phase 1 and 2 studies.  
 
 
 	 	
	  
  
 
 
Where:  fu is unbound (free) fraction of phenytoin. 
             Cu is unbound (filtrate) concentration of 
phenytoin. 
             Ct is total concentration of phenytoin. 
 
3. RESULTS 
 
Plasma protein binding of phenytoin was 
evaluated by ultrafiltration technique. Protein 
binding of three phenytoin concentrations was 
studied: 25, 50, and 100 µg/mL. 
The assessment of nonspecific binding to the 
micropartition system yielded negligible binding 
(fraction unbound ~ 1) to the units. Table 1 
represents phenytoin protein binding results. 
 
Phase 1 study formed a reference line of 
phenytoin protein binding values. Mean free 
fraction value of phenytoin was 0.14 in this 
phase. This finding was consistent with 
previously published data [8,9,10]. No significant 
difference in protein binding was noted within the 
study group. 
 
Phase 2 was performed to evaluate effect of TZX 
on protein binding of phenytoin. Mean free 
fraction value of phenytoin was 0.48 with no 
significant difference within this study group. 
Tizoxanide significantly increased unbound 
phenytoin concentrations by 4.4, 3.7, and 2.8-
fold for concentrations of 25 µg/mL, 50 µg/mL, 
and 100 µg/mL, respectively 
 
4. DISCUSSION 
 
This investigation was performed to evaluate the 
potential effect of tizoxanide on protein binding of 
phenytoin. Phenytoin was of particular interest 
because of its high protein binding, narrow 
therapeutic window and non-linear 
pharmacokinetics. Since phenytoin is a highly 
protein bound drug, it was imperative to analyze 
the effect of another extremely protein bound 
drug on unbound concentrations of phenytoin. 
Tizoxanide fits these criteria and is expected to 
be co-administered with phenytoin in clinical 
practice.  
 
The research revealed statistically significant 
interaction between phenytoin and tizoxanide. 
TZX significantly inhibited protein binding of PHT 
in all concentrations tested. Phenytoin was 
displaced from protein binding sites what 
resulted in amplified unbound plasma levels of 
the antiepileptic drug.  
 
The both medications phenytoin and tizoxanide 
are bound primarily to albumins and competed 
for the same binding site of the proteins. 
Albumins have two main drug binding sites, 
Sudlow site I and Sudlow site II [33,34]. Drug 
binding to these sites is selective. Tizoxanide 
primarily binds to Sudlow site I [35]. Since 
tizoxanide displaced phenytoin, it can be 
assumed that PHT also binds to site I. The 
bindings resulted in direct competition for the 
shared Sudlow site I. This hypothesis requests 
further examination. 
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Table 1. Protein binding of phenytoin (PHT) in phase 1 and 2 studies 
 
Study groups PHT concentrations (µg/mL) Fraction unbound of PHT* 
Phase 1 
PHT alone 
100 0.17 (0.004) 
50 0.13 (0.001) 
25 0.11 (0.001) 
Phase 2 
PHT + TZX 
100 0.47 (0.005) 
50 0.48 (0.007) 
25 0.48 (0.005) 
*Data reported as mean (SD) 
 
Non-linear pharmacokinetics makes phenytoin 
dosing is extremely challenging. Moreover, other 
drugs may modify the pharmacokinetics of 
phenytoin by altering its plasma protein binding 
and/or metabolism. It is commonly recognized 
that only unbound phenytoin is pharmacologically 
active. The development of side effects 
correlates better with free phenytoin 
concentrations than with total phenytoin 
concentrations [36,37]. Metabolism of some 
medications including PHT depends on unbound 
fractions of the drugs. Protein binding inhibition 
of drugs with linear PK lead to an increase in free 
plasma levels, greater extent of metabolism, 
increased clearance, and lower total 
concentrations. Such interactions may result in 
reduced effectiveness of the therapies. However, 
non-linear PK makes the outcomes of phenytoin 
protein binding interaction unpredictable. In case 
of saturated metabolism, the total concentration 
of phenytoin is often at the same level as before 
the drug interaction occurred, but unbound 
phenytoin concentrations are much higher. Such 
interaction may result in phenytoin 
poisonousness. If only total phenytoin 
concentrations are measured, clinicians may be 
under the impression that no drug interaction 
happened. Unbound concentrations have to be 
measured whenever possible with suspected 
abnormal phenytoin plasma protein binding to 
avoid phenytoin intoxication. 
 
Previous studies have focused on the interaction 
between valproic acid and phenytoin. Valproic 
acid is a highly protein bound anticonvulsant. 
Phenytoin unbound concentrations were 
increased by 50% via coadministration with 
valproic acid [38]. This interaction has produced 
serious side effects. Data from the present study 
indicate that tizoxanide increased phenytoin 
unbound concentration more than 50%. PHT as 
a narrow therapeutic index drug poses major 
changes in the pharmacological effect with only 
small variations in unbound concentrations. Non-
linear PK makes the difference even more 
dangerous and can produce phenytoin 
intoxication. Greater uptake of phenytoin into the 
brain due to increased unbound level
 
can lead to 
serious neuronal side effects [39]. When highly 
protein bound drugs are coadministered with 
phenytoin, complete blood count, liver function, 
cardiac function, respiratory function and 
suicidality are among an extensive list of 
monitoring parameters to be assessed [40]. 
 
The protein binding inhibition of phenytoin can 
lead to changes in unbound concentrations and, 
as a result, alteration in the clinical effect. To 
avoid an unexpected change in pharmacologic 
response, monitoring of unbound concentrations 
is mandated and dose adjustments should be 
implemented.  
 
5. CONCLUSION 
 
This investigation provided an important 
understanding of protein binding displacement 
interactions. Protein binding drug-drug interaction 
was detected between phenytoin and tizoxanide. 
TZX significantly inhibited protein binding of 
phenytoin in human plasma. Therefore, 
tizoxanide has the potential to modify protein 
binding of PHT and rise free phenytoin 
concentrations in patients. In addition, PHT is a 
narrow therapeutic range drug and has non-
linear pharmacokinetics what make the drug-
drug interaction even more complex. The 
interaction could lead to great variations in 
therapeutic response and result in amplified 
toxicity of phenytoin treatment. For these 
reasons, phenytoin dose adjustment may be 
necessary when co-administered with 
nitazoxanide. Further studies are needed to 
assess clinical significance of the finding as well 
as find a strategy to improve clinical outcomes 
and avoid toxicity of phenytoin therapy.  
 
Caution also should be taken when administering 
nitazoxanide concurrently with other highly 
plasma protein-bound drugs, especially drugs 
with narrow therapeutic indices, as competition 
for binding sites may occur. The pharmacokinetic 
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alterations may result in complex changes in total 
and unbound concentrations and drug response. 
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